New England Research & Management, Inc. Vertex Pharmaceuticals Inc Transaction History
New England Research & Management, Inc.
- $213 Million
- Q3 2024
A detailed history of New England Research & Management, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, New England Research & Management, Inc. holds 4,575 shares of VRTX stock, worth $1.82 Million. This represents 1.0% of its overall portfolio holdings.
Number of Shares
4,575
Previous 2,735
67.28%
Holding current value
$1.82 Million
Previous $1.28 Million
65.99%
% of portfolio
1.0%
Previous 0.62%
Shares
9 transactions
Others Institutions Holding VRTX
# of Institutions
1,724Shares Held
221MCall Options Held
1.58MPut Options Held
1.36M-
Capital World Investors Los Angeles, CA26.8MShares$10.7 Billion1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.2MShares$9.2 Billion0.2% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$8.47 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.8MShares$4.69 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA9MShares$3.58 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $102B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...